Integrated molecular pathology: the Belfast model

- Clinical outcomes are the measure of quality in science.
- Much of the failure in biomarker discovery and validation is related to the way we understand and deliver molecular pathology activities.
- The current model for cancer discovery and treatment is not sustainable.
- An integrated model for molecular pathology provision is likely to overcome some of the existing barriers in biomarker validation and adoption.